Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AE 941

Drug Profile

AE 941

Alternative Names: Arthrovas; Neoretna; Neovastat; Psovascar; Shark cartilage extract AE 941

Latest Information Update: 17 Aug 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AEterna Zentaris Inc
  • Class Antineoplastics; Antipsoriatics
  • Mechanism of Action Angiogenesis inhibitors; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Age-related macular degeneration; Breast cancer; Multiple myeloma; Non-small cell lung cancer; Osteoarthritis; Prostate cancer; Psoriasis; Renal cancer; Rheumatoid arthritis

Most Recent Events

  • 05 Mar 2007 Discontinued - Phase-III for Non-small cell lung cancer in Canada (PO)
  • 05 Mar 2007 Discontinued - Phase-III for Non-small cell lung cancer in USA (PO)
  • 17 Feb 2006 The US National Cancer Institute has interrupted enrolment in a phase III trial for Non-small cell lung cancer in the USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top